Apalutamide

ERLEADA

NADAC/unit N/A

No Shortage Tier 1: 35.9% PA Req: 198.8% 1 Manufacturers 1 ANDAs

ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen r....

Covered Lives

Generic Manufacturers

JANSSEN BIOTECH INCZYDUS WORLDWIDE DMCC

Explore in the Ecosystem

rxsaver.aiCompare prices for Apalutamide drfinder.aiFind doctors who prescribe Apalutamide rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Apalutamide

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.